Navigation Links
Savient Submits Biologics License Application (BLA) for pegloticase
Date:10/31/2008

EAST BRUNSWICK, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the submission of its BLA to the U.S. Food and Drug Administration (FDA) seeking approval to market pegloticase in the United States along with its request for a priority review. Savient's filing includes data from both the six-month placebo controlled Phase 3 pivotal trials, as well as data from the Open Label Extension (OLE) study. The data set includes 101 patients with at least twelve months continuous treatment.

"Filing the BLA for pegloticase is a major milestone for Savient," said Christopher Clement, President and Chief Executive Officer. "This filing reflects our commitment to changing the paradigm of therapy available to the treatment-failure gout population and brings us one step closer to commercializing this drug and offering a solution to patients who suffer from this debilitating disease."

The two replicate, six-month, Phase 3 clinical trials for pegloticase were performed under the auspices of a Special Protocol Assessment (SPA) and pegloticase was granted Orphan Drug designation by the FDA. The OLE study was established to allow patients who completed the Phase 3 program the opportunity to continue to receive pegloticase for an extended period of time.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  The Council for Entrepreneurial Development (CED), ... the country, today released a mid-year update to ... It showed that in the first half ... startups in the technology, life science, advanced manufacturing ... a variety of sources. Significant investment in technology companies ...
(Date:9/16/2014)... SANTA BARBARA, Calif. , Sept. 16, 2014 ... Material Strength index (BMSi) test identifies patients with ... tests cannot.  Over 160 million people worldwide are ... be detected by today,s standard bone strength test, ... at the 2014 American Society for Bone and ...
(Date:9/16/2014)... RENU 28, the world's first and only skin ... purchase in Australia and New Zealand in mid-August . , ... The tour will make stops in Brisbane on September 16, ... Sydney on the 20th, and Melbourne on the 22nd. , ... and to educate people about the new product and business ...
(Date:9/15/2014)... 15, 2014  FlexTech Alliance today issued a ... product demonstrators (demos) and a functional electronic print ... pre-proposals due on October 22, 2014 and full ... ultimately selected are provided by the US Army ... share by the proposing organization. Photo ...
Breaking Biology Technology:CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... Jan. 19, 2012  SynCardia Systems, Inc. ( www.syncardia.com ... Heart, announced today that on Dec. 29, 2011, ... Total Artificial Heart patient, 61-year-old Nikola Gaspic, to ... using the Freedom® portable driver . ...
... -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... that specializes in patented biopharmaceutical medicine, modernized ... active pharmaceutical ingredients (API) announced the Company ... certification for its 250-ton Jiangchuan Macrolide Facility ...
...  Synthetic Genomics Inc. (SGI), a privately held company commercializing ... of global challenges, today announced they have hired George ... is a proven leader with experience in developing sophisticated ... and nutritional products for humans and animals. At SGI ...
Cached Biology Technology:Slovenia's 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the FreedomĀ® Portable Driver 2Slovenia's 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the FreedomĀ® Portable Driver 3TPI Receives GMP Certification for JCM Facility 2TPI Receives GMP Certification for JCM Facility 3Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2
(Date:9/16/2014)... The risk of severe maternal morbidity amongst women ... suggests a new study published today (17 September) ... and Gynaecology . , Australians generally enjoy high ... that health disparities exist, in particular between indigenous ... aimed to explore the independent impact of socioeconomic ...
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... Pit Fire began on September 13, 2014. The fire ... is currently over 2,300 acres in size and is mostly ... Pit Fire was calm Monday night due to higher humidity. ... anchor point and beginning to construct a fireline on the ... resources are working on the fire: , 7 20-person Crews, ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... Obese women are as much as 28 percent ... pregnancy, according to research that earned a Michigan State ... Barbara Luke, a researcher in the MSU College of ... focused on data of nearly 50,000 women using assisted ...
... the UCLA Henry Samueli School of Engineering and Applied ... the laboratory the enzyme responsible for producing the blockbuster ... published Oct. 23 in the journal Science , ... with similarly beneficial effects. The ...
... at Chicago have received $1 million from the National ... between "fat taxes" and food consumption, diet quality and ... made available through the American Recovery and Reinvestment Act ... rates associated with restaurants and with specific sugar- and ...
Cached Biology News:MSU researcher: Obesity significantly cuts odds of successful pregnancy 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2UIC receives $1 million grant to study 'fat taxes,' diet, obesity 2
... SDSaway reagent is a valuable tool for ... The presence of SDS in biological samples ... bound SDS-protein complex, inhibits enzymatic activity during ... as a contaminant in mass spectrometry analyses. ...
... cGMP Safe Deposit Service ECACC is able ... requirements of cGMP for cryo-storage. The cell lines ... they have been produced in accordance with the ... tested for freedom from mycoplasma, bacteria or fungi. ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... has 20 years of expertise in the ... still offers the most powerful systems on ... to 40 000 in-microplate tests requiring incubation ... of different modules (such as worktable shaker ...
Biology Products: